Why Quest Diagnostics Fell Nearly 7% Today
Wednesday wasn't a great day to be a Quest Diagnostics (NYSE: DGX) investor. The company's shares took a nearly 7% hit "thanks" to preliminary results that clearly didn't meet investor expectations.
According to those figures, Quest was expected to post $2.74 billion in revenue for its Q4. This would represent a decline of 9%, compared to the same quarter the previous year. This occurred despite the fact that the company's total base-testing volumes outside of its COVID-19 testing services rose 10% against the pre-pandemic Q4 2019 figure.
Image source: Getty Images.
Source Fool.com
